Key result
Therapy with epsilon-aminocaproic acid rapidly normalized fibrinogen levels in a man with metastatic prostate cancer and DIC, whereas high-dose estrogen therapy failed to correct the coagulopathy.
Why the study?
Does epsilon-aminocaproic acid improve coagulopathy in a patient with metastatic prostate cancer and DIC?
Case Report (n=1)
Does epsilon-aminocaproic acid improve coagulopathy in a patient with metastatic prostate cancer and DIC?
Epsilon-aminocaproic acid successfully corrected coagulopathy in a patient with metastatic prostate cancer and DIC with excessive fibrinolysis.
Answers are grounded in this paper and cite their sources.
Epsilon-aminocaproic acid may normalize fibrinogen in refractory prostate cancer DIC; single case leaves open need for controlled studies.
BACKGROUND: Disseminated intravascular coagulation (DIC) and primary fibrinolysis have both been reported in association with prostate carcinoma. The correct diagnosis of the coagulopathy can be difficult and the appropriate management controversial. METHODS: A case is presented of a man in whom DIC and soft tissue hemorrhage developed after prostatic biopsy. The results of therapy and a review of the literature are discussed. RESULTS: Fibrinogen levels continued to decrease despite high-dose estrogen therapy, but they rapidly returned to normal after therapy with epsilon-aminocaproic acid. Although routine coagulation tests were suggestive of primary fibrinolysis, the results of the D-dimer assay confirmed that the patient had DIC associated with excessive fibrinolysis. CONCLUSION: A review of the literature suggests that most cases of primary fibrinolysis are probably DIC with excessive secondary fibrinolysis. In cases in which bleeding is the primary manifestation of DIC and there is a significant reduction in alpha-2-plasmin inhibitor activity, a trial of epsilon-aminocaproic acid and low-dose heparin should be considered. The failure in this case of estrogen therapy to correct the coagulopathy, despite a later good tumor response, is consistent with the delay in which anorchid testosterone levels are obtained after initiating treatment.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (1992) conducted a case report in Metastatic prostate cancer with disseminated intravascular coagulation and excessive fibrinolysis (n=1). Epsilon-aminocaproic acid vs. High-dose estrogen therapy (prior treatment) was evaluated on Fibrinogen levels and coagulopathy resolution. Therapy with epsilon-aminocaproic acid rapidly normalized fibrinogen levels in a man with metastatic prostate cancer and DIC, whereas high-dose estrogen therapy failed to correct the coagulopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: